KRAS and cancer: Alterations in the KRAS isoform account for 75–85% of RAS-mutant cancers [10, 11], with mutations at G12 accounting for 81% of these [11], and are mainly associated with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC) [12].